For people carrying a serious diagnosis — and the families carrying it with them — psychedelic-assisted therapy has shown a remarkable ability to ease the fear and depression that illness brings. Gently, legally, and with real support.
Yes. In randomised trials at Johns Hopkins and NYU, a single supervised psilocybin session produced rapid, sustained reductions in depression and anxiety in people with cancer, with about 80% still improved at six months. It is done gently, in coordination with the person's medical team.
The illness gets the doctors. These are the things that too often get nothing — and they are treatable.
The landmark studies in this field weren’t about addiction or PTSD — they were about people facing death. In matched 2016 trials at Johns Hopkins and NYU, a single psilocybin session with therapeutic support produced rapid and lasting relief of the depression and anxiety that come with life-threatening cancer (Griffiths et al.; Ross et al., Journal of Psychopharmacology, 2016).
Patients consistently described something medicine rarely offers: not sedation of the fear, but a changed relationship with it — meaning, connection, and peace that persisted at six months and, in long-term follow-ups, years later. Researchers call it existential distress; families call it getting their person back for the time that matters.
We help you find legal, gentle, well-run settings for this work — psilocybin programs where they are lawful, ketamine-assisted therapy at home in the U.S. — with screening that respects your medical reality and support that includes the people around you.
This is some of the strongest evidence in all of psychedelic medicine — read it directly.
Substantial, sustained decreases in depression and anxiety after one session; ~80% maintained relief at 6 months (Griffiths et al., n=51).
Immediate, clinically significant reduction of existential distress, sustained at follow-up (Ross et al., n=29).
The majority of surviving participants still rated it among the most meaningful experiences of their lives.
The right option depends on health, mobility, and time — an advisor walks it through with you and your family.
The treatment behind the landmark cancer-distress trials — in legal, supported settings.
Explore Psilocybin →Available at home, works quickly on depression, and fits alongside ongoing medical care.
Explore Ketamine →It doesn’t disappear — it stops running the household.
The things that needed saying get said, while there’s time to say them.
Days measured in moments that matter instead of appointments.
Not resignation — peace. Patients describe the difference vividly.
The strongest evidence is in existential distress, but the science is now reaching into the illnesses themselves. Here is where it actually stands — named studies, honest labels.
Cancer & end-of-life anxiety. The landmark work is Johns Hopkins’ randomized, double-blind trial of 51 patients with life-threatening cancer: a single high-dose psilocybin session produced large, sustained drops in depression and anxiety, with about 80% still showing clinically significant relief at six months (Griffiths et al., Journal of Psychopharmacology, 2016). A parallel NYU trial reached strikingly similar results (Ross et al., 2016).
Parkinson’s disease. In a 2024 open-label pilot at UC San Francisco, 12 people with Parkinson’s plus depression or anxiety received psilocybin with therapy. The team reported clinically meaningful improvements in mood, cognition, and — unexpectedly — motor function that persisted for weeks, with no serious adverse events (published in Neuropsychopharmacology, 2025). A larger randomized UCSF–Yale trial is now underway.
Dementia & early Alzheimer’s. Johns Hopkins is running an active trial of psilocybin for depression in people with mild cognitive impairment or early Alzheimer’s (NCT04123314) — built on the finding that depression accelerates cognitive decline, so easing it may matter for patients and caregivers alike. Early-stage and unproven for the disease itself, but a serious line of inquiry.
Ibogaine & neurodegeneration. This one is the most preliminary — and the most talked-about. In animal models, ibogaine and its metabolite noribogaine raise levels of GDNF, a growth factor that supports the dopamine neurons lost in Parkinson’s (Carnicella et al. and others). It does not regenerate neurons; it appears to create conditions friendlier to neural resilience. In 2025 Ambio Life Sciences opened the first clinical ibogaine program for neurodegenerative conditions, and early case reports in progressive MS have described measurable changes. Promising signal, not proof — and we say so plainly.
One honest caveat that applies to all of the above: much of this work is early, small, or observational. None of it makes any treatment a cure, and some of it may not hold up. What it does establish is that these are serious, actively studied avenues — worth understanding clearly rather than through hope or hype.
Serious illness is never carried alone. Neither is this decision.
Spouses and adult children join most of these conversations — sometimes leading them. We help families ask the right questions, understand what a session involves, and plan support for after. Consent and pace belong to the person facing the illness; the preparation can belong to everyone.
Call or text (866) 435-7057 — you set the pace. Family on the line is welcome whenever you want them there.
Diagnosis, treatment schedule, medications, and what your care team advises — nothing proceeds around them.
Screening coordinated with your treating physicians, timed around treatment cycles when needed.
Programs experienced with serious illness, vetted to our standard — introduced only when you're ready.
Integration for you and the people who love you. This work is about the time you have, not just the session.
No — and anyone who tells you otherwise should worry you. This is about the fear, depression, and existential distress that serious illness brings. That’s where the research shows psychedelic-assisted therapy can help profoundly. It is not a cancer treatment and we will never present it as one.
In two landmark 2016 trials at Johns Hopkins and NYU, a single supported psilocybin session produced rapid, substantial, and sustained reductions in depression and anxiety in patients with life-threatening cancer — about 80% still showed clinically significant relief six months later (Griffiths et al.; Ross et al., Journal of Psychopharmacology, 2016). Follow-ups years later found many still described it as among the most meaningful experiences of their lives.
That depends entirely on the individual picture, which is why real medical screening — your diagnosis, treatments, medications, and heart health — comes before any conversation about booking. Reputable providers coordinate with your medical reality rather than working around it. That screening is the first thing we verify.
Yes, and we encourage it. Serious illness happens to families, not just patients. We regularly work with spouses and adult children — sometimes it’s the family member who reaches out first. Everything stays confidential either way.
A gentle, confidential conversation about what’s possible — for you or for someone you love. Families welcome. No pressure, ever.
Speak With An Advisor →Psilocybin has the strongest evidence for existential distress in serious illness. Ketamine is a legal US option for rapid relief. Ibogaine is generally not appropriate here because of its cardiac demands.
Sessions are scheduled around treatment and reviewed with the oncology team. Some medications need adjusting; the clinic plans this during intake.
Yes. Programs we recommend welcome a family member in preparation and integration; many patients say that is where the change lands.
Call or text (866) 435-7057 or request a consultation. We coordinate gently and only with your care team's knowledge.
